TACE Combined With Anlotinib Treatment of Middle-advanced Hepatocellular Carcinoma (HCC) Patients
Condition: Carcinoma, Hepatocellular Interventions: Device: TACE; Drug: Anlotinib Hydrochloride Sponsor: Zhejiang Cancer Hospital Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer & Oncology | Carcinoma | Hepatocellular Carcinoma | Hospitals | Liver Cancer | Research